Agilon Health upgraded to Buy from Hold at Jefferies

Jefferies analyst Jack Slevin upgraded Agilon Health (AGL) to Buy from Hold with a price target of $48, up from $27.50. The company’s “strong” Q1 results and “clear signs” of improved trend visibility bring an “exceedingly positive” risk/reward skew for the shares, the analyst tells investors in a research note. The firm says that with “supportive” Medicare Advantage rates locked in for 2026 and 2027, and payors likely still on a margin focused pricing path, the outlook for Agilon has been improving.